Phase 1Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Sponsored by Vironexis Biotherapeutics Inc.
About this study
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Enrolling at this location
Cleveland Clinic
Cleveland, Ohio
I'm interestedThis study also enrolls at 10 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.